Clinical Neuroimmunology of CCL3 in Brain Tumors

$3.24M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Duke University
Country	United States
Start Date	May 01, 2024
End Date	Apr 30, 2029
Duration	1,825 days
Number of Grantees	3
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10857036`

Grant Description

ABSTRACT: Malignant primary brain tumors represent the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma. Glioblastoma (GBM) is uniformly lethal, and current therapy is non-specific and produces a median overall survival of